Newsroom

Bone marrow showing a loss of blood cells in mice after radiation (left) and then after treatment with the PTP-sigma inhibitor (right), where the recovery of blood cells is visible.
Researcher Daniel Geschwind smiles in his office before a bookshelf.
Cellular images of a young mouse prostate (left) and a prostate in an older mouse (right). The older prostate contains more luminal progenitor cells (brown).
Microscopic images show a non-small cell breast cancer, left, and small cell neuroendocrine breast cancer, right. Small cell neuroendocrine cancers typically feature smaller cells and larger nuclei in relation to cell size.
Headshot of S. Thomas Carmichael in a lab coat
Microscopic images of a normal heart valve in a mouse, left, and a heart valve grown in a lab with heart-derived macrophages blocked, right. Without those macrophages, the valves are thick and deformed.
Research by UCLA’s Gay Crooks, Amélie Montel-Hagen and Christopher Seet could point the way toward “off-the-shelf” T cell therapies that are more readily available to patients.
Led by Dr. Donald Kohn and Katelyn Masiuk, the researchers engineered a “viral vector” that would turn on the FoxP3 gene only in regulatory T cells — and not in other types of cells.